Protective effects of inhibitors of nitric oxide synthase in immune complex-induced vasculitis. 1992

M S Mulligan, and S Moncada, and P A Ward
Department of Pathology, University of Michigan Medical School, Ann Arbor 48109.

1. The ability of analogues of L-arginine (N-iminoethyl-L-ornithine (L-NIO), NG-monomethyl-L-arginine (L-NMMA), NG-nitro-L-arginine methyl ester (L-NAME) and NG-nitro-L-arginine (L-NNA)) to protect against inflammatory injury induced by activated neutrophils was investigated in rats following intradermal or intrapulmonary deposition of immune complexes. 2. The descending order of potency for protective effects of these analogues was: L-NIO > L-NMMA > L-NNA = L-NAME. The approximate IC50 value for L-NIO in the dermal vasculitis model was 65 microM. For all other compounds, the IC50 values were > 5 mM. 3. The protective effect of L-NIO in the skin was reversed in a dose-dependent manner by the presence of L-arginine, but not by D-arginine. L-Arginine also reversed the protective effects of L-NIO in immune complex-induced lung injury. 4. The protective effects of L-NIO were not associated with reductions in neutrophil accumulation, as measured by extraction from tissues of myeloperoxidase. 5. These data demonstrate that L-NIO has the most potent protective effects against immune complex-induced vascular injury induced by activated macrophages. Furthermore, they indicate that this injury is dependent upon the generation of nitric oxide.

UI MeSH Term Description Entries
D007105 Immune Complex Diseases Group of diseases mediated by the deposition of large soluble complexes of antigen and antibody with resultant damage to tissue. Besides SERUM SICKNESS and the ARTHUS REACTION, evidence supports a pathogenic role for immune complexes in many other IMMUNE SYSTEM DISEASES including GLOMERULONEPHRITIS, systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC) and POLYARTERITIS NODOSA. Hypersensitivity, Type III,Type III Hypersensitivity,Disease, Immune Complex,Diseases, Immune Complex,Hypersensitivities, Type III,Immune Complex Disease,Type III Hypersensitivities
D008297 Male Males
D009195 Peroxidase A hemeprotein from leukocytes. Deficiency of this enzyme leads to a hereditary disorder coupled with disseminated moniliasis. It catalyzes the conversion of a donor and peroxide to an oxidized donor and water. EC 1.11.1.7. Myeloperoxidase,Hemi-Myeloperoxidase,Hemi Myeloperoxidase
D009952 Ornithine An amino acid produced in the urea cycle by the splitting off of urea from arginine. 2,5-Diaminopentanoic Acid,Ornithine Dihydrochloride, (L)-Isomer,Ornithine Hydrochloride, (D)-Isomer,Ornithine Hydrochloride, (DL)-Isomer,Ornithine Hydrochloride, (L)-Isomer,Ornithine Monoacetate, (L)-Isomer,Ornithine Monohydrobromide, (L)-Isomer,Ornithine Monohydrochloride, (D)-Isomer,Ornithine Monohydrochloride, (DL)-Isomer,Ornithine Phosphate (1:1), (L)-Isomer,Ornithine Sulfate (1:1), (L)-Isomer,Ornithine, (D)-Isomer,Ornithine, (DL)-Isomer,Ornithine, (L)-Isomer,2,5 Diaminopentanoic Acid
D000542 Alveolitis, Extrinsic Allergic A common interstitial lung disease caused by hypersensitivity reactions of PULMONARY ALVEOLI after inhalation of and sensitization to environmental antigens of microbial, animal, or chemical sources. The disease is characterized by lymphocytic alveolitis and granulomatous pneumonitis. Allergic Alveolitis, Extrinsic,Hypersensitivity Pneumonitis,Pneumonitis, Hypersensitivity,Allergic Alveolitides, Extrinsic,Alveolitides, Extrinsic Allergic,Extrinsic Allergic Alveolitides,Extrinsic Allergic Alveolitis,Hypersensitivity Pneumonitides,Pneumonitides, Hypersensitivity
D000594 Amino Acid Oxidoreductases A class of enzymes that catalyze oxidation-reduction reactions of amino acids. Acid Oxidoreductases, Amino,Oxidoreductases, Amino Acid
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001120 Arginine An essential amino acid that is physiologically active in the L-form. Arginine Hydrochloride,Arginine, L-Isomer,DL-Arginine Acetate, Monohydrate,L-Arginine,Arginine, L Isomer,DL Arginine Acetate, Monohydrate,Hydrochloride, Arginine,L Arginine,L-Isomer Arginine,Monohydrate DL-Arginine Acetate
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D018366 Vasculitis, Leukocytoclastic, Cutaneous Disorder characterized by a vasculitic syndrome associated with exposure to an antigen such as a drug, infectious agent, or other foreign or endogenous substance. Its pathophysiology includes immune complex deposition and a wide range of skin lesions. Hypersensitivity or allergy is present in some but not all cases. Angiitis, Hypersensitivity,Cutaneous Leukocytoclastic Vasculitis,Hypersensitivity Angiitis,Hypersensitivity Vasculitis,Vasculitis, Hypersensitivity,Allergic Cutaneous Angiitis,Allergic Cutaneous Vasculitis,Angiitis, Allergic Cutaneous,Cutaneous Allergic Vasculitis,Cutaneous Leukocytoclastic Angiitis,Vasculitis, Allergic Cutaneous,Allergic Cutaneous Angiitides,Allergic Cutaneous Vasculitides,Allergic Vasculitides, Cutaneous,Allergic Vasculitis, Cutaneous,Angiitides, Allergic Cutaneous,Angiitides, Cutaneous Leukocytoclastic,Angiitides, Hypersensitivity,Angiitis, Cutaneous Leukocytoclastic,Cutaneous Allergic Vasculitides,Cutaneous Angiitides, Allergic,Cutaneous Angiitis, Allergic,Cutaneous Leukocytoclastic Angiitides,Cutaneous Leukocytoclastic Vasculitides,Cutaneous Vasculitides, Allergic,Cutaneous Vasculitis, Allergic,Hypersensitivity Angiitides,Hypersensitivity Vasculitides,Leukocytoclastic Angiitides, Cutaneous,Leukocytoclastic Angiitis, Cutaneous,Leukocytoclastic Vasculitides, Cutaneous,Leukocytoclastic Vasculitis, Cutaneous,Vasculitides, Allergic Cutaneous,Vasculitides, Cutaneous Allergic,Vasculitides, Cutaneous Leukocytoclastic,Vasculitides, Hypersensitivity,Vasculitis, Cutaneous Allergic,Vasculitis, Cutaneous Leukocytoclastic

Related Publications

M S Mulligan, and S Moncada, and P A Ward
February 1998, General pharmacology,
M S Mulligan, and S Moncada, and P A Ward
January 2000, Methods in molecular medicine,
M S Mulligan, and S Moncada, and P A Ward
April 1994, Kidney international,
M S Mulligan, and S Moncada, and P A Ward
January 1997, Brain research,
M S Mulligan, and S Moncada, and P A Ward
January 2004, Journal of the Chinese Medical Association : JCMA,
M S Mulligan, and S Moncada, and P A Ward
September 1997, Acta anaesthesiologica Sinica,
M S Mulligan, and S Moncada, and P A Ward
January 2007, Pharmacological reports : PR,
M S Mulligan, and S Moncada, and P A Ward
October 1997, Gastroenterology,
M S Mulligan, and S Moncada, and P A Ward
January 1996, Experimental eye research,
Copied contents to your clipboard!